Research programme: HuMax-HepC antibodies - Genmab

Drug Profile

Research programme: HuMax-HepC antibodies - Genmab

Alternative Names: HuMax-HepC

Latest Information Update: 18 Mar 2011

Price : $50

At a glance

  • Originator Connex; INSERM
  • Developer Genmab
  • Class Antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 18 Mar 2011 No development reported - Preclinical for Hepatitis C in Denmark (Parenteral)
  • 21 May 2007 Preclinical data added to the Viral Infections pharmacodynamics section
  • 12 Aug 2003 Preclinical trials in Hepatitis C in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top